|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|---|
| Revenue, net | |||
| Cost of revenue | |||
| Gross profit | |||
| Operating expenses | |||
| Selling, general and administrative | |||
| Research and development | |||
| Impairment on assets held for sale | |||
| Impairment on goodwill | |||
| Total operating expenses | |||
| Loss from operations | |||
| Other income (expense) | |||
| Long-term debt forgiveness | |||
| Investment Income, Interest | |||
| Total investment Income, Interest | |||
| Interest expense | |||
| Loss on disposal of assets | |||
| Change in fair value of earnout liabilities | |||
| Change in fair value of warrant liabilities | |||
| Other income | |||
| Total other income, net | |||
| Loss before income tax expense | |||
| Income tax expense | |||
| Net loss | |||
| Total net loss | |||
| Deemed dividend - Earnout Shares | |||
| Net loss attributable to common stockholders | |||
| Net loss per share: | |||
| Basic (in dollars per share) | |||
| Diluted (in dollars per share) | |||
| Basic (in dollars per share) | |||
| Diluted (in dollars per share) | |||
| Weighted average common shares outstanding: | |||
| Basic (in dollars per share) | |||
| Diluted (in dollars per share) | |||
| Other comprehensive income (loss) | |||
| Foreign currency translation adjustment | |||
| Comprehensive loss | |||
Loading...